Current News:

• Cyto Pulse, the Karolinska Institute and the Swedish Institute for Infectious Disease Control Receive Phase I Clinical Trial Approval from the Swedish Medical Products Agency to Evaluate an HIV Vaccine in Healthy Volunteers

• MERIAL Receives Full License Approval for ONCEPT(TM) Canine Melanoma Vaccine

• Bioject Establishes Strategic Alliance with MPI Research

• Bioject Closes Previously Announced Equity Financing

• Bioject Reports Third Quarter 2009 Results (Audio)

• Bioject Reports Third Quarter 2009 Results

• Bioject to Report Third Quarter 2009 Financial Results

• Bioject Reports Second-Quarter 2009 Financial Results (Audio)

• Bioject Reports Second-Quarter 2009 Financial Results

• Bioject Reports First Quarter 2009 Financial Results

• Bioject Signs CRADA with US Navy to Study a Malaria Vaccine

• Bioject Meets Milestone for Merial Limited

• Bioject Announces FDA Market Clearance for the Zetajet™ Needle-Free Injection Therapy System

• Fourth Quarter and Year-End 2008 Financial Results (Audio)

• Bioject Reports December 31, 2008 Results

• Bioject Enters into a Collaborative Research Agreement with IAVI for the Delivery of an HIV Vaccine Candidate

• Bioject Extends Supply Agreement with Ferring Pharmaceuticals, Inc.

• SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial

• U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vical's Vaxfectin(R) Adjuvant